{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:40:09Z","timestamp":1746344409744,"version":"3.40.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk associated with immune effector cell-associated neurotoxicity syndrome and pseudoprogression, patients with central nervous system (CNS) involvement are less likely to receive CAR T-cell therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients concerns:<\/jats:title>\n            <jats:p>We report a case of a 61-year-old, male patient with intravascular large B-cell lymphoma who suffered a CNS relapse after standard chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>A diagnosis of intravascular large B-cell lymphoma with CNS involvement was made.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We treated the patient using CAR T-cell therapy following a conditioning regimen consisting of thiotepa and busulfan and autologous stem cell transplantation. Although he experienced grade 1 cytokine release syndrome, no other serious adverse events, such as immune effector cell-associated neurotoxicity syndrome or pseudoprogression, were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient achieved complete remission after the CAR T-cell infusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>CAR T-cell therapy following autologous stem cell transplantation is a viable option for relapsed\/refractory lymphoma with CNS infiltration. Further clinical studies are warranted to verify its safety and efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027733","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T20:39:40Z","timestamp":1639082380000},"page":"e27733","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma"],"prefix":"10.1097","volume":"100","author":[{"given":"Yu","family":"Yagi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-2008","authenticated-orcid":false,"given":"Yusuke","family":"Kanemasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Ohigashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kishida","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Shimizuguchi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Omuro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/cancers11010047","article-title":"Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: efficacy and safety-a systematic review with meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Ann Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00277-016-2744-5","article-title":"Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model","volume":"95","author":"Kanemasa","year":"2016","journal-title":"Ann Hematol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","article-title":"Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience","volume":"89","author":"Shimazu","year":"2009","journal-title":"Int J Hematol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1080\/1042819031000097393","article-title":"Intravascular B-cell lymphoma: report of two cases with different clinical presentation but rapid central nervous system involvement","volume":"44","author":"Anghel","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1440-1827.2004.01613.x","article-title":"Intravascular large B-cell lymphoma presenting with mass lesions in the central nervous system: a report of five cases","volume":"54","author":"Imai","year":"2004","journal-title":"Pathol Int"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1532\/IJH97.06033","article-title":"Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy","volume":"84","author":"Ohno","year":"2006","journal-title":"Int J Hematol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1349-7006.2010.01555.x","article-title":"Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients","volume":"101","author":"Shimada","year":"2010","journal-title":"Cancer Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3324\/haematol.2012.070839","article-title":"Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project","volume":"98","author":"Bromberg","year":"2013","journal-title":"Haematologica"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s12185-015-1874-1","article-title":"Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement","volume":"102","author":"Lee","year":"2015","journal-title":"Int J Hematol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/10428194.2015.1026901","article-title":"Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan\/thiotepa-based conditioning and autologous stem cell transplant","volume":"57","author":"Oh","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clml.2017.08.100","article-title":"High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement","volume":"17","author":"Qualls","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10428194.2014.916800","article-title":"Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide","volume":"56","author":"Welch","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3109\/10428190903288456","article-title":"Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation","volume":"50","author":"Patil","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?","volume":"56","author":"Ghafouri","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"(Suppl 1)","key":"R28-20250504","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2019-127659","article-title":"Anti-CD19 CAR T therapy following autologous HSCT may be safe and effective in patients with refractory large B-cell lymphoma","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-010-0497-x","article-title":"Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?","volume":"104","author":"Omuro","year":"2011","journal-title":"J Neurooncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:03:25Z","timestamp":1746342205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027733"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":32,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027733","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"2021-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}